Minnesota Medicaid spending on GLP-1 drugs

How much did Minnesota Medicaid spend on GLP-1 drugs like Ozempic and Mounjaro in 2025?

Pharmacies were reimbursed at least $255.7 million for GLP-1 drugs paid through Minnesota Medicaid in 2025, across at least 230,594 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 79 rows of 337, so these figures are floors.

Pharmacies were reimbursed at least $56.1 million for GLP-1 drugs paid through Minnesota Medicaid in 2026 (quarter 1 only, as posted so far), across at least 50,352 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 18 rows of 85, so these figures are floors.

By year and ingredient

2020at least $2,602,833No data$21,021,768at least $3,756,129at least $6,352,820Suppressedat least $19,030at least $33,752,579
2021at least $4,698,366No dataat least $31,194,940at least $5,046,612at least $6,098,121at least $64,846Suppressedat least $47,102,885
2022at least $10,281,239at least $334,855$38,601,957at least $5,869,597at least $10,948,133at least $41,492Suppressedat least $66,077,273
2023at least $48,037,703at least $4,464,833$44,522,000at least $6,966,788at least $15,340,282at least $30,254Suppressedat least $119,361,860
2024at least $114,820,442at least $27,388,652at least $16,594,156at least $4,747,466at least $10,287,720$70,064Suppressedat least $173,908,499
2025at least $191,976,038at least $51,182,475at least $6,283,119at least $4,628,384at least $1,626,530SuppressedSuppressedat least $255,696,545
2026 (Q1)at least $41,378,642at least $12,389,680at least $949,398$1,334,842No dataSuppressedNo dataat least $56,052,562

By product, 2025

Ozempicat least $71,554,860at least 73,42811 of 35
Rybelsusat least $1,605,585at least 1,4809 of 25
Wegovy$118,815,59390,9880 of 40
Mounjaroat least $18,463,299at least 17,8276 of 54
Zepboundat least $32,719,175at least 31,4249 of 56
Liraglutide (generic name listing)at least $2,177,405at least 4,41420 of 47
Saxenda$2,441,7292,0910 of 8
Victoza$1,663,9852,6120 of 16
Trulicityat least $4,628,384at least 4,2995 of 32
Bydureonat least $1,626,530at least 2,0312 of 7
ByettaSuppressedSuppressed6 of 6
Exenatide (generic name listing)SuppressedSuppressed3 of 3
SoliquaSuppressedSuppressed4 of 4
XultophySuppressedSuppressed4 of 4

By quarter, 2025

Q1 2025at least $56,695,570at least 51,40620 of 83
Q2 2025at least $64,862,779at least 58,60822 of 84
Q3 2025at least $66,238,170at least 59,57418 of 85
Q4 2025at least $67,900,026at least 61,00619 of 85

By quarter, 2026 (posted so far)

Q1 2026at least $56,052,562at least 50,35218 of 85

The amounts are CMS’s “Total Amount Reimbursed” field. CMS’s data dictionary for State Drug Utilization Data says of it:

“This total is not reduced or affected by Medicaid rebates paid to the state. This amount represents both the Federal and State Reimbursement and is inclusive of dispensing fees.”

Its prescription count is “The number of prescriptions reimbursed (by the Medicaid Program ONLY) to pharmacists for the (11-digit NDC) drug for the period covered.”

CMS suppresses some rows (its “Suppression Used” field is true and the counts and amounts are left blank). Here a suppressed row is never counted as zero: a figure that includes suppressed rows is shown as “at least” the sum of the rows CMS did publish, and a figure where every row is suppressed is shown as “Suppressed.” The “Rows suppressed” column gives the count. Where many rows are suppressed, the published sum can be well below the full amount, so floors for different states are not directly comparable.

Fee-for-service and managed care rows are added together. Other states: Medicare and Medicaid spending on GLP-1 drugs.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.